US Stock MarketDetailed Quotes
CTOR Citius Oncology
- 1.080
- +0.010+0.93%
Trading Dec 13 11:13 ET
77.01MMarket Cap-4.70P/E (TTM)
1.120High1.070Low22.14KVolume1.070Open1.070Pre Close24.38KTurnover0.42%Turnover RatioLossP/E (Static)71.30MShares49.00052wk High1.60P/B5.67MFloat Cap0.85052wk Low--Dividend TTM5.25MShs Float49.000Historical High--Div YieldTTM4.67%Amplitude0.850Historical Low1.101Avg Price1Lot Size
Citius Oncology Key Stats
Quarterly+Annual
YOY
| (FY)Sep 30, 2023 | (FY)Sep 30, 2022 | |
|---|---|---|
| Total revenue | 0 | 0 |
| Operating revenue | --0 | --0 |
| Cost of revenue | ||
| Gross profit | ||
| Operating expense | 149.58%12.12M | 4.86M |
| Selling and administrative expenses | 451.59%7.88M | --1.43M |
| -General and administrative expense | 451.59%7.88M | --1.43M |
| Research and development costs | 23.71%4.24M | --3.43M |
| Operating profit | -149.58%-12.12M | -4.86M |
| Net non-operating interest income expense | ||
| Other net income (expense) | ||
| Income before tax | -149.58%-12.12M | -4.86M |
| Income tax | 0.00%576K | 576K |
| Net income | -133.72%-12.7M | -5.43M |
| Net income continuous Operations | -133.72%-12.7M | ---5.43M |
| Minority interest income | ||
| Net income attributable to the parent company | -133.72%-12.7M | -5.43M |
| Preferred stock dividends | ||
| Other preferred stock dividends | ||
| Net income attributable to common stockholders | -133.72%-12.7M | -5.43M |
| Basic earnings per share | -133.72%-0.1782 | -0.0763 |
| Diluted earnings per share | -133.72%-0.1782 | -0.0763 |
| Dividend per share | ||
| Currency Unit | USD | USD |
Heat List
US
Overall
Symbol
Price
% Chg
No Data